AFX-3772 is a conjugate vaccine commercialized by GSK, with a leading Phase II program in Streptococcal Pneumonia. According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of AFX-3772’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for AFX-3772 is expected to reach an annual total of $17 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
AFX-3772 Overview
GSK-5101955A (ASP-3772) is under development for the prevention of Streptococcus pneumoniae infections for adults and infants. It is administered through intramuscular and subcutaneous route. It has valency of 24, and it is a conjugate vaccine that contains a particular ratio of pneumococcal polysaccharides and pneumococcal proteins. It is developed based on multiple antigens presenting system (MAPS) technology platform.
GSK Overview
GSK is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
For a complete picture of AFX-3772’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.